NCT04741464View on ClinicalTrials.gov

Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis

NAActive, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 2, 2021

Primary Completion Date

November 22, 2023

Study Completion Date

November 30, 2025

Conditions
Deep Vein ThrombosisInflammatory Response
Interventions
DRUG

Tinzaparin

"Tinzaparin 20 000 anti-Xa IU/mL dispensed in graduated syringes of 0.5 mL, 0.7 mL and 0.9 mL at the dose of 175IU/Kg/d.~Strategy: Tinzaparin 175 UI/Kg/d for 21 days After this time the physician will continue the treatment of his choice to treat DVT."

Trial Locations (1)

80480

CHU Amiens, Amiens

All Listed Sponsors
lead

Centre Hospitalier Universitaire, Amiens

OTHER